Invest1 publisher2 min readPublished
Boston Scientific withdraws a 2026 earnings range it had set four cents wide
The device maker told regulators that an August 25 intrusion halted order processing and manufacturing, and the next company figure on the year comes with third-quarter results on October 28, 64 days after the incident was identified.
The Investor · Invest desk
What happened
- Boston Scientific said on Tuesday it no longer expects to meet its previously issued third-quarter and full-year 2026 sales and adjusted profit forecasts, after a cybersecurity incident hit global operations.
- Unauthorized activity on some IT systems, first identified on August 25, caused a network outage that cut access to operating systems and business applications and disrupted manufacturing and order shipment.
- Guidance issued in July had put 2026 adjusted earnings at $3.28 to $3.32 a share and reported net sales growth at 5.5% to 6.5%.
- Boston Scientific plans to give an update on the operational and financial impact of the incident when it reports third-quarter results on October 28.
Compiled by The InvestorSomething wrong?How this is made
Why it matters
- decision Anyone pricing the stock over the next seven weeks has to size the revenue hole on their own, since the first official figure comes with third-quarter results.
- constraint Because the company expects only a portion of the lost revenue back, some of the quarter is gone for good, and the size of that portion sets the ceiling on any restated year.
- contradiction The filing pairs a nearly complete operational restart with an impact the company calls uncertain, so restored uptime cannot be used as evidence that the customer orders returned.
- precedent With Abbott, Stryker, Medtronic, Clover Health and Novo Nordisk among healthcare names recently hit, a mid-quarter guidance pull after an IT outage now sits inside the range of normal outcomes for device manufacturers.
A range four cents wide on a $3.30 midpoint is a company saying it knows its year. Boston Scientific set that range in July, alongside reported sales growth of 5.5% to 6.5%, and it put the third quarter at 80 to 82 cents [3][4]. In proportional terms the annual bracket was the tighter of the two: 1.2% of midpoint against 2.5% for the quarter [1][2].
The quarter the outage landed in carries roughly a quarter of the year's earnings, 81 cents at midpoint against $3.30, or 24.5% [4]. The company withdrew both forecasts without replacing either number. Boston Scientific plans to account for the incident when it reports on October 28, which is 64 days after the unauthorized activity was first identified [8][2][3].
The operational side of the filing is close to resolved. Sterilization facilities are operational, manufacturing has resumed across most sites globally, and major distribution centres are processing and shipping orders at or above normal levels [6]. The order book is the open question. Boston Scientific said it expects to recover a portion of the lost revenue as it fulfils customer orders and reduces backlogs, and that the full financial impact remains uncertain [5]. A stent order a hospital could not place in the first week of September either queues or goes to a competitor's catalogue, and the split between those two decides how much of the quarter comes back.
If the queued orders convert, the full year lands near the old range and the withdrawal was bookkeeping. If hospitals sourced elsewhere and stayed there, the loss shows up in the growth rate. Or the sales line recovers and the cost migrates into remediation expense and gross margin, where it is harder to isolate. I lean toward the first, because distribution centres back at or above normal within about two weeks of August 25 is a short window for a hospital to requalify a supplier [6][2]. The filing does not include a dollar figure, so that is a judgement about the duration of the disruption and not about the size of the bill.
What would break it: a third-quarter sales decline deeper than a two-week interruption can explain, or a lowered multi-year growth path on October 28.
Shares were down 2.1% before the bell [9]. For a company that had just pulled a quarter and a year without replacing either number, a 2.1% mark suggests investors also read the damage as timing.
What to watch
- Whether the October 28 update restates the full year inside, below, or nowhere near the withdrawn $3.28 to $3.32 range.
- Any disclosure of data exfiltration, ransom payment, insurance recovery, or a quantified remediation charge.
- Whether fourth-quarter sales growth runs above the withdrawn 5.5% to 6.5% path, which is what backlog conversion would look like.